DAIICHI-SANKYO
Daiichi Sankyo Europe (hereafter, Daiichi Sankyo) today announced the launch of the Future of Heart Health in Europe: A Holistic Care Think Tank report. The report follows the first-of-its-kind holistic care Think Tank meeting, held earlier this year, which brought together influential representatives from various disciplines including clinicians, patient advocates, researchers, digital and media experts and policy specialists. Three strategic recommendations for incorporating a holistic approach to CV care in Europe arose from the meeting:
-
Improve lifelong support and education:
- Improving lifelong support and education from a young age to lay a strong foundation for sustained wellness; introducing programmes in the workplace that reward physical and mental well-being.
-
Increase interdisciplinary collaboration and communication:
- Assigning a patient case manager and embracing implementation of artificial intelligence to improve communication and coordination of interdisciplinary collaboration.
-
Changes in health policies across Europe:
- A holistic view of CV care should be included on political agendas at a European level. Policy changes will lead to better access to preventative care, support for the adoption of a healthy lifestyle, and removal of barriers to equitable healthcare.
Across Europe, CVD is responsible for the loss of 10,000 lives every day.3 However, cardiovascular conditions are largely preventable, and there is a growing emphasis on addressing the burden of CVD through behavioural changes and risk factor management. The holistic care Think Tank included experts with a focus on behavioural and physiological factors for CVD, such as diet, exercise, and mental health. These experts play a vital role in raising awareness of the various aspects of CVD and, together, can build a more holistic picture of a person’s health that goes beyond the view of the heart alone.
"Collaborating with a diverse array of stakeholders is paramount in adopting a truly holistic approach to heart health in Europe,” said Berk Kiran, Vice President, Commercial Operations Europe, Daiichi Sankyo Europe. “By harnessing the unique perspectives and expertise of individuals across disciplines, sectors, and backgrounds, we can help forge innovative solutions that address the challenges facing cardiovascular health today. Together, we can drive meaningful change and pave the way towards a healthier future for all."
“At a political level, I think that it's time to establish health promotion and cardiovascular prevention as a real priority,” said Professor Hélder Dores, Cardiologist, Portugal and member of the Think Tank. “In healthcare, I think that not only for cardiologists but for all the professionals, it’s important to amend how we’re determining an individual’s risk and to improve lifestyle, because as we know, the great majority of atherosclerotic events could be prevented if we address the underlying risk factors.”
The inaugural Think Tank meeting and report form part of Daiichi Sankyo’s ongoing heart health initiative: We Care for Every Heartbeat (WC4EHB).
For further information on holistic approaches to CV health and care in Europe and to read the full report please visit our WC4EHB website: https://wecareforeveryheartbeat.com/.
-ENDS-
About We Care for Every Heartbeat
At Daiichi Sankyo we care for every heartbeat. Our goal is to protect people from cardiovascular disease and help those who suffer from it, so they can enjoy every precious moment that life has to offer. Under the WC4EHB umbrella, Daiichi Sankyo regularly publishes informational blogs designed to improve health literacy and CVD care across Europe. We have conducted awareness surveys to uncover the public perception and attitude towards heart disease. We are working with external organisations, such as The Economist and the European Nutrition for Health Alliance (ENHA), to better understand the burden of CVD in Europe, and we partner with health specialists across a range of CV-relevant professions to advocate for greater collaboration and a holistic approach in Europe. We have made a long-term commitment to invest and work tirelessly to help patients and inspire positive change in CV care. For further information on WC4EHB and our activities, visit our website: https://wecareforeveryheartbeat.com/.
About CVD in Europe
CVD – a group of disorders affecting the heart and circulatory system, which can lead to heart attacks and strokes – is the primary cause of death in Europe, accounting for 45% of all deaths in the region and responsible for more than 10,000 lives lost every day.3,4,5,6 Furthermore, a large proportion of these deaths are premature – occurring before the age of 65 years – with CVD responsible for almost a quarter of premature deaths among men and nearly a fifth among women in Europe.7 Despite its high prevalence and burden, a lack of public awareness and gaps in understanding, especially of CVD risk factors, may be preventing those at risk from making positive lifestyle changes and adopting healthy habits to help reduce their CVD risk.8
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need.
For more information, please visit www.daiichisankyo.com
References |
_____________________________ |
1 World Health Organization. Cardiovascular Diseases (CVDs) Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed May 2024. |
2 Luengo-Fernandez, R., et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023. 00: 1–16. |
3 Mach, F., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020. 41;(1): 111–188. |
4 European Heart Network. European Cardiovascular Disease Statistics 2017 edition. Available at: https://ehnheart.org/wp-content/uploads/2023/07/CVD-Statistics.pdf. Last accessed May 2024. |
5 European Heart Network. CVD Statistics. Available at: https://ehnheart.org/about-cvd/the-burden-of-cvd/. Last accessed May 2024. |
6 Eurostat. Causes of death statistics. Available at: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Causes_of_death_statistics#Major_causes_of_death_in_the_EU_in_2020. Last accessed May 2024. |
7 European Heart Network. Fighting cardiovascular disease – a blueprint for EU action. Available at: https://www.escardio.org/static-file/Escardio/Advocacy/Documents/2020%20ESC-EHN-blueprint_digital%20edition.pdf. Last accessed May 2024. |
8 Daiichi Sankyo We Care for Every Heartbeat. European Survey Report of Cardiovascular Disease – Uncovering current public perceptions and attitudes towards cardiovascular disease. Available at: wecareforeveryheartbeat.com/wp-content/uploads/2023/08/European_Survey_Report_final_approved_Jul_2022.pdf. Last accessed May 2024. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520608896/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom